AMG 757 Studie A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer (Aktiv)
Encephalon Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases (ENCEPHALON) (Aktiv)
Erstlinie
AMG 20200469 A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (Aktiv)
CRISP Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (Aktiv)
Dolphin A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in patients with local limited small cell lung cancer (Aktiv)
IMforte A Phase III, randomized, open-label, multicenter study of Lurbinectedin in combination with Atezolizumab compared with Atezolizumab as maintanence therapy in participants with extensive - stage SCLC following first-line induction therapy with carboplatin, Etoposid and Atezolizumab (Aktiv)
MO43989 Liquid1st An International Prospective Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer (L1ST) (Aktiv)
Zweitlinie oder später
20200491 DeLLphi Eine Phase-2-Studie zur Beurteilung der Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von AMG 757 bei Patienten mit rezidiviertem/refraktärem kleinzelligem Lungenkarzinom nach mindestens zwei vorangegangenen Therapielinien (Aktiv)
BI 1438-0002 A Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3. (Aktiv)
BI 1438-0009/ DAREON-9 DAREON-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With Topotecan for the Treatment of Patients With Small Cell Lung Cancer (Aktiv)
DAREON™-5 / 1438-0005 An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas (Aktiv)
DLL3 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)
PM1183-C-008-21 A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial) (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)